EA201190209A1 - Соединения для лечения метаболических расстройств - Google Patents

Соединения для лечения метаболических расстройств

Info

Publication number
EA201190209A1
EA201190209A1 EA201190209A EA201190209A EA201190209A1 EA 201190209 A1 EA201190209 A1 EA 201190209A1 EA 201190209 A EA201190209 A EA 201190209A EA 201190209 A EA201190209 A EA 201190209A EA 201190209 A1 EA201190209 A1 EA 201190209A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
metabolic disorders
connections
diabetes
possess
Prior art date
Application number
EA201190209A
Other languages
English (en)
Inventor
Оскар Барба
Сюзан Хелен Дэвис
Мэттью Колин Тор Файф
Ревати Перпетуа Дживаратнам
Карен Лесли Скофилд
Томас Штароске
Алан Джон Уилльям Стюарт
Саймон Эндрю Суэйн
Дэвид Мэттью Уитхолл
Original Assignee
Прозидион Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прозидион Лимитед filed Critical Прозидион Лимитед
Publication of EA201190209A1 publication Critical patent/EA201190209A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

Настоящее изобретение относится к терапевтическим соединениям, которые обладают активностью агонистов GPR119 (сопряженный с G-белком рецептор 119) и полезны для лечения метаболических расстройств, включая диабет типа II.
EA201190209A 2009-03-12 2010-03-12 Соединения для лечения метаболических расстройств EA201190209A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0904287.0A GB0904287D0 (en) 2009-03-12 2009-03-12 Compounds for the treatment of metabolic disorders
PCT/GB2010/050442 WO2010103335A1 (en) 2009-03-12 2010-03-12 Compounds for the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
EA201190209A1 true EA201190209A1 (ru) 2012-04-30

Family

ID=40600949

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201190209A EA201190209A1 (ru) 2009-03-12 2010-03-12 Соединения для лечения метаболических расстройств

Country Status (18)

Country Link
US (1) US20120040953A1 (ru)
EP (1) EP2406256A1 (ru)
JP (1) JP2012520284A (ru)
KR (1) KR20110130476A (ru)
CN (1) CN102395584A (ru)
AU (1) AU2010222673A1 (ru)
BR (1) BRPI1009781A2 (ru)
CA (1) CA2754794A1 (ru)
CL (1) CL2011002221A1 (ru)
EA (1) EA201190209A1 (ru)
GB (1) GB0904287D0 (ru)
IL (1) IL215051A0 (ru)
MA (1) MA33242B1 (ru)
MX (1) MX2011009491A (ru)
PE (1) PE20120356A1 (ru)
SG (1) SG174362A1 (ru)
WO (1) WO2010103335A1 (ru)
ZA (1) ZA201107446B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077214A1 (es) 2009-06-24 2011-08-10 Neurocrine Biosciences Inc Heterociclos nitrogenados y composiciones farmaceuticas que los contienen
JP5467151B2 (ja) 2009-06-24 2014-04-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
GB201006167D0 (en) * 2010-04-14 2010-05-26 Prosidion Ltd Compounds for the treatment of metabolic disorders
GB2488360A (en) * 2011-02-25 2012-08-29 Prosidion Ltd Heterocyclic GPCR agonists
GB201114389D0 (en) * 2011-08-22 2011-10-05 Prosidion Ltd Novel compounds
AR083904A1 (es) * 2010-11-18 2013-04-10 Prosidion Ltd Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
KR101881932B1 (ko) 2011-12-07 2018-07-27 삼성전자주식회사 자기 소자 및 그 제조 방법
JP2015522080A (ja) 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
WO2018165520A1 (en) * 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
TW202229260A (zh) * 2019-07-15 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 可用為幾丁質酶抑制劑的經取代的胺基三唑

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100042A (en) 1993-03-31 2000-08-08 Cadus Pharmaceutical Corporation Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor
GB9719496D0 (en) 1997-09-13 1997-11-19 Glaxo Group Ltd G protien chimeras
WO2000012705A2 (en) 1998-09-01 2000-03-09 Basf Aktiengesellschaft Methods for improving the function of heterologous g protein-coupled receptors
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
CA2549955A1 (en) * 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
JP4980928B2 (ja) 2004-12-24 2012-07-18 プロシディオン・リミテッド Ｇタンパク質共役受容体（ｇｐｒ１１６）作動薬および肥満および糖尿病治療のためのその使用
EP1838706A1 (en) * 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
JP2008545008A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
AU2006264649A1 (en) 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
GB0513257D0 (en) * 2005-06-30 2005-08-03 Prosidion Ltd Compounds
AU2006264651A1 (en) 2005-06-30 2007-01-11 Prosidion Limited G-protein coupled receptor agonists
CN101379028A (zh) 2006-02-09 2009-03-04 阿斯利康(瑞典)有限公司 化学化合物
JP2009532453A (ja) 2006-04-06 2009-09-10 プロシディオン・リミテッド ヘテロサイクリックｇｐｃｒアゴニスト
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
GB0610746D0 (en) 2006-06-01 2006-07-12 Prosidion Ltd Method of treatment
WO2007148185A2 (en) 2006-06-21 2007-12-27 Pfizer Products Inc. Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
EA015835B1 (ru) * 2006-12-06 2011-12-30 Смитклайн Бичем Корпорейшн Производные 4-окса(тиа)метилпиперидина и их применение в качестве противодиабетических средств
CA2674525A1 (en) 2006-12-22 2008-07-03 Albert Einstein College Of Medicine Of Yeshiva University Azetidine analogues of nucleosidase and phosphorylase inhibitors
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
AR064735A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr y composicion farmaceutica en base al compuesto
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
JP2010514828A (ja) 2007-01-04 2010-05-06 プロシディオン・リミテッド ピペリジンｇｐｃｒアゴニスト
EP2114936A1 (en) 2007-01-04 2009-11-11 Prosidion Limited Piperidine gpcr agonists
US20080186971A1 (en) 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
DK2170864T3 (da) 2007-07-17 2012-01-16 Bristol Myers Squibb Co Pyridon-GPR119-G-protein-koblede receptoragonister
US20100286112A1 (en) 2007-09-10 2010-11-11 Oscar Barba Compounds for the treatment of metabolic disorders
US8568899B2 (en) 2007-10-18 2013-10-29 Jx Nippon Mining & Metals Corporation Metal covered polyimide composite, process for producing the composite, and process for producing electronic circuit board
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
CN101621337B (zh) 2008-06-30 2013-08-07 华为技术有限公司 一种时延调节装置与方法
GB0812641D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds
EP2321308B9 (en) 2008-07-10 2012-08-08 Prosidion Limited Piperidine gpcr agonists
AU2009269772A1 (en) 2008-07-10 2010-01-14 Prosidion Limited Piperidinyl GPCR agonists
GB0812648D0 (en) 2008-07-10 2008-08-20 Prosidion Ltd Compounds

Also Published As

Publication number Publication date
PE20120356A1 (es) 2012-04-16
US20120040953A1 (en) 2012-02-16
MA33242B1 (fr) 2012-05-02
ZA201107446B (en) 2012-06-27
JP2012520284A (ja) 2012-09-06
KR20110130476A (ko) 2011-12-05
MX2011009491A (es) 2011-10-11
IL215051A0 (en) 2011-11-30
AU2010222673A1 (en) 2011-11-03
EP2406256A1 (en) 2012-01-18
BRPI1009781A2 (pt) 2016-03-08
GB0904287D0 (en) 2009-04-22
WO2010103335A1 (en) 2010-09-16
CA2754794A1 (en) 2010-09-16
CN102395584A (zh) 2012-03-28
SG174362A1 (en) 2011-11-28
CL2011002221A1 (es) 2012-07-06

Similar Documents

Publication Publication Date Title
EA201190209A1 (ru) Соединения для лечения метаболических расстройств
EA201190208A1 (ru) Соединения для лечения метаболических расстройств
EA201190207A1 (ru) Соединения для лечения метаболических расстройств
EA201101524A1 (ru) Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA200870424A1 (ru) Способы применения рецептора gpr119 для идентификации соединений, которые можно использовать для увеличения костной массы субъекта
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MA32975B1 (fr) Antagonistes de c5ar
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA200970835A1 (ru) Индазолы, применяемые для лечения расстройств, опосредуемых эстрогеновым рецептором бета
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
EP2560660A4 (en) THERAPIES BASED ON CHEMOSOUS RECEPTOR LIGANDS
EA201170151A1 (ru) Пиперидиниловые агонисты gpcr
EA201200975A1 (ru) Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
MX2009011358A (es) Derivados de pirimidinona y metodos para su uso.
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119